X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA GLENMARK PHARMA NATCO PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 34.4 14.1 243.5% View Chart
P/BV x 17.5 4.0 442.6% View Chart
Dividend Yield % 0.7 0.3 203.5%  

Financials

 NATCO PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
GLENMARK PHARMA
Mar-16
NATCO PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs8771,262 69.5%   
Low Rs424672 63.1%   
Sales per share (Unadj.) Rs223.4270.6 82.6%  
Earnings per share (Unadj.) Rs31.124.9 124.9%  
Cash flow per share (Unadj.) Rs40.334.4 117.0%  
Dividends per share (Unadj.) Rs5.002.00 250.0%  
Dividend yield (eoy) %0.80.2 371.7%  
Book value per share (Unadj.) Rs219.5151.3 145.0%  
Shares outstanding (eoy) m33.07282.16 11.7%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.93.6 81.4%   
Avg P/E ratio x20.938.9 53.9%  
P/CF ratio (eoy) x16.128.1 57.5%  
Price / Book Value ratio x3.06.4 46.4%  
Dividend payout %16.18.0 200.2%   
Avg Mkt Cap Rs m21,504272,778 7.9%   
No. of employees `000NA10.0 0.0%   
Total wages/salary Rs m1,12813,782 8.2%   
Avg. sales/employee Rs ThNM7,614.9-  
Avg. wages/employee Rs ThNM1,374.8-  
Avg. net profit/employee Rs ThNM700.2-  
INCOME DATA
Net Sales Rs m7,38976,340 9.7%  
Other income Rs m167356 46.9%   
Total revenues Rs m7,55676,696 9.9%   
Gross profit Rs m1,79314,172 12.7%  
Depreciation Rs m3042,691 11.3%   
Interest Rs m3661,789 20.5%   
Profit before tax Rs m1,29010,048 12.8%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3093,028 10.2%   
Profit after tax Rs m1,0277,019 14.6%  
Gross profit margin %24.318.6 130.7%  
Effective tax rate %23.930.1 79.4%   
Net profit margin %13.99.2 151.2%  
BALANCE SHEET DATA
Current assets Rs m3,68159,096 6.2%   
Current liabilities Rs m3,12340,018 7.8%   
Net working cap to sales %7.625.0 30.2%  
Current ratio x1.21.5 79.8%  
Inventory Days Days8975 119.4%  
Debtors Days Days59119 49.2%  
Net fixed assets Rs m7,68539,075 19.7%   
Share capital Rs m331282 117.2%   
"Free" reserves Rs m6,67030,281 22.0%   
Net worth Rs m7,25942,703 17.0%   
Long term debt Rs m95524,873 3.8%   
Total assets Rs m11,957111,026 10.8%  
Interest coverage x4.56.6 68.3%   
Debt to equity ratio x0.10.6 22.6%  
Sales to assets ratio x0.60.7 89.9%   
Return on assets %11.77.9 146.9%  
Return on equity %14.216.4 86.1%  
Return on capital %20.717.5 118.3%  
Exports to sales %39.443.3 90.9%   
Imports to sales %5.77.4 76.7%   
Exports (fob) Rs m2,90833,044 8.8%   
Imports (cif) Rs m4215,672 7.4%   
Fx inflow Rs m3,44536,945 9.3%   
Fx outflow Rs m70361,066 1.2%   
Net fx Rs m2,743-24,122 -11.4%   
CASH FLOW
From Operations Rs m1,4403,449 41.8%  
From Investments Rs m-1,089-8,802 12.4%  
From Financial Activity Rs m-3536,986 -5.0%  
Net Cashflow Rs m-1934 -0.2%  

Share Holding

Indian Promoters % 52.0 48.3 107.7%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 6.9 113.6%  
FIIs % 16.6 34.4 48.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 10.5 247.6%  
Shareholders   25,395 56,727 44.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   J.B.CHEMICALS  SUVEN LIFE  CIPLA  ELDER PHARMA  VENUS REMEDIES  

Compare NATCO PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Tata Global Beverages Surges 8.3%(Closing)

Indian share markets snapped their losing streak of last week and finished the trading day on a strong note due to strong buying momentum in FMCG stocks, metal stocks and auto stocks.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Other Income Boosts Profit Growth (Quarterly Results Update - Detailed)

Sep 6, 2016

Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Aug 16, 2017 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - VENUS REMEDIES COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS